JP2016196440A - サイトグロビン発現増強剤 - Google Patents
サイトグロビン発現増強剤 Download PDFInfo
- Publication number
- JP2016196440A JP2016196440A JP2015077604A JP2015077604A JP2016196440A JP 2016196440 A JP2016196440 A JP 2016196440A JP 2015077604 A JP2015077604 A JP 2015077604A JP 2015077604 A JP2015077604 A JP 2015077604A JP 2016196440 A JP2016196440 A JP 2016196440A
- Authority
- JP
- Japan
- Prior art keywords
- cytoglobin
- fgf
- expression
- cells
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010053020 Cytoglobin Proteins 0.000 title claims abstract description 109
- 239000003623 enhancer Substances 0.000 title claims abstract description 36
- 102000016554 Cytoglobin Human genes 0.000 title claims abstract 9
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims abstract description 44
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims abstract description 44
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims abstract description 21
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims abstract description 21
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 201000007270 liver cancer Diseases 0.000 claims description 19
- 208000014018 liver neoplasm Diseases 0.000 claims description 19
- 230000002265 prevention Effects 0.000 claims description 15
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 230000003902 lesion Effects 0.000 claims description 6
- 230000007882 cirrhosis Effects 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 abstract description 14
- 230000009471 action Effects 0.000 abstract description 3
- 102100034126 Cytoglobin Human genes 0.000 description 100
- 210000004024 hepatic stellate cell Anatomy 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 29
- 239000013589 supplement Substances 0.000 description 22
- 238000000034 method Methods 0.000 description 14
- 230000002708 enhancing effect Effects 0.000 description 12
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 11
- 230000004913 activation Effects 0.000 description 10
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000012091 fetal bovine serum Substances 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 102000007469 Actins Human genes 0.000 description 7
- 108010085238 Actins Proteins 0.000 description 7
- 230000003472 neutralizing effect Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 206010021143 Hypoxia Diseases 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000000302 ischemic effect Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 101000846416 Homo sapiens Fibroblast growth factor 1 Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- 230000020411 cell activation Effects 0.000 description 5
- 238000012790 confirmation Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000001146 hypoxic effect Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 229940049954 penicillin Drugs 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 210000000651 myofibroblast Anatomy 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 102000018146 globin Human genes 0.000 description 3
- 108060003196 globin Proteins 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 230000008810 intracellular oxidative stress Effects 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- YCYMCMYLORLIJX-SNVBAGLBSA-N (2r)-2-propyloctanoic acid Chemical compound CCCCCC[C@H](C(O)=O)CCC YCYMCMYLORLIJX-SNVBAGLBSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 2
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 2
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 2
- 241000272534 Struthio camelus Species 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229950005776 arundic acid Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 201000006334 interstitial nephritis Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 101150081880 FGF1 gene Proteins 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100030856 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- WBNQDOYYEUMPFS-UHFFFAOYSA-N N-nitrosodiethylamine Chemical compound CCN(CC)N=O WBNQDOYYEUMPFS-UHFFFAOYSA-N 0.000 description 1
- 102100035411 Neuroglobin Human genes 0.000 description 1
- 108010026092 Neuroglobin Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 231100000700 hepatocarcinogen Toxicity 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- -1 pH adjusters Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000002705 pancreatic stellate cell Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000002100 tumorsuppressive effect Effects 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
項1. FGF−1及びFGF−2からなる群より選択される少なくとも1種を有効成分とする、サイトグロビン発現増強剤。
項2. 肝癌、肝線維化、又は肝硬変の予防乃至治療に使用される、項1に記載のサイトグロビン発現増強剤。
項3. 肝癌以外の癌の治療予防乃至治療に使用される、項1に記載のサイトグロビン発現増強剤。
項4. 間質病変の予防乃至治療に使用される、項1に記載のサイトグロビン発現増強剤。
本発明のサイトグロビン発現増強剤は、有効成分として、FGF−1及びFGF−2からなる群より選択される少なくとも1種を使用する。
本発明のサイトグロビン発現増強剤は、前記有効成分の他に、治療対象となる疾患の種類に応じて、他の薬理活性成分を含んでいてもよい。
本発明のサイトグロビン発現増強剤の剤型については、特に制限されず、その投与形態等に応じて適宜設定すればよい。本発明のサイトグロビン発現増強剤の剤型として、具体的には、注射剤、シロップ剤、細胞懸濁液、リポソーム製剤等の液状製剤;錠剤、硬カプセル剤、軟カプセル剤、顆粒剤、散剤、丸剤等の固形状製剤等が挙げられる。また、注射剤にする場合には、使用前に生理食塩水等で溶解する用時調製用粉末(例えば凍結乾燥粉末)の形態であってもよい。
本発明のサイトグロビン発現増強剤は、生体内でサイトグロビンの発現を増強できるので、サイトグロビンの発現増強によって予防乃至治療効果が期待される疾患に適用して使用される。
本発明のサイトグロビン発現増強剤の投与形態としては、例えば、局所投与、皮下投与、腹腔内投与、筋肉内投与、静脈内投与、経直腸的、皮内投与等の非経口投与;経口投与が挙げられ、適用する疾患の種類等に応じて適宜設定すればよい。本発明のサイトグロビン発現増強剤の投与形態として、好ましくは非経口投与が挙げられる。
60mmプレートに、ヒト肝星細胞株(HHSteC)細胞を5×105cells/well播種し、Supplement(SteCGS, Cat. No. 5352)、2%ウシ胎児血清(FBS)、ペニシリン、及びストレプトマイシンを添加したSteCM培地(ScienCell,Cat.No.5300)にて、約24時間培養した。
60mmプレートに、ヒト肝星細胞株(HHSteC)細胞を5×105cells/well播種し、Supplement(SteCGS, Cat. No. 5352)、2%ウシ胎児血清(FBS)、ペニシリン、及びストレプトマイシンを添加したSteCM培地(ScienCell,Cat.No.5300)にて、約24時間培養した。
35mmプレートに、ヒト肝星細胞株(HHSteC)細胞を5×105cells/well播種し、Supplement(SteCGS, Cat. No. 5352)、2%ウシ胎児血清(FBS)、ペニシリン、及びストレプトマイシンを添加したSteCM培地(ScienCell,Cat.No.5300)にて、約24時間培養した。
4wellチャンバースライドに、HHSteC細胞2×104cells/wellとなるように播種し、約24時間培養した。培養は、Supplement、2%FBS、ペニシリン、及びストレプトマイシンを添加したSteCM培地(ScienCell Research Laboratories製、Cat.No.5300)を用いて行った。
60mmプレートに、ヒト肝星細胞株(HHSteC)細胞を5×105cells/well播種し、Supplement(SteCGS, Cat. No. 5352)、2%ウシ胎児血清(FBS)、ペニシリン、及びストレプトマイシンを添加したSteCM培地(ScienCell,Cat.No.5300)にて、約24時間培養した。
Claims (4)
- FGF−1及びFGF−2からなる群より選択される少なくとも1種を有効成分とする、サイトグロビン発現増強剤。
- 肝癌、肝線維化、又は肝硬変の予防乃至治療に使用される、請求項1に記載のサイトグロビン発現増強剤。
- 肝癌以外の癌の治療予防乃至治療に使用される、請求項1に記載のサイトグロビン発現増強剤。
- 間質病変の予防乃至治療に使用される、請求項1に記載のサイトグロビン発現増強剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015077604A JP6675150B2 (ja) | 2015-04-06 | 2015-04-06 | サイトグロビン発現増強剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015077604A JP6675150B2 (ja) | 2015-04-06 | 2015-04-06 | サイトグロビン発現増強剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016196440A true JP2016196440A (ja) | 2016-11-24 |
JP6675150B2 JP6675150B2 (ja) | 2020-04-01 |
Family
ID=57358226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015077604A Active JP6675150B2 (ja) | 2015-04-06 | 2015-04-06 | サイトグロビン発現増強剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6675150B2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109265553A (zh) * | 2018-08-23 | 2019-01-25 | 许瑞安 | 一种细胞珠蛋白与方格星虫纤溶酶的融合蛋白 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004520295A (ja) * | 2000-12-15 | 2004-07-08 | サルザー バイオロジクス インコーポレイテッド | 腎損傷の治療方法 |
WO2005097988A1 (ja) * | 2004-03-23 | 2005-10-20 | Dnavec Research Inc. | 組織の維持および/または修復に関連する骨髄関連細胞 |
JP2013525309A (ja) * | 2010-04-16 | 2013-06-20 | ソーク インスティチュート フォー バイオロジカル スタディーズ | Fgfを用いて代謝障害を処置するための方法 |
WO2014084027A1 (ja) * | 2012-11-28 | 2014-06-05 | 独立行政法人放射線医学総合研究所 | 細胞膜透過性の線維芽細胞増殖因子の医療用途 |
-
2015
- 2015-04-06 JP JP2015077604A patent/JP6675150B2/ja active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004520295A (ja) * | 2000-12-15 | 2004-07-08 | サルザー バイオロジクス インコーポレイテッド | 腎損傷の治療方法 |
WO2005097988A1 (ja) * | 2004-03-23 | 2005-10-20 | Dnavec Research Inc. | 組織の維持および/または修復に関連する骨髄関連細胞 |
JP2013525309A (ja) * | 2010-04-16 | 2013-06-20 | ソーク インスティチュート フォー バイオロジカル スタディーズ | Fgfを用いて代謝障害を処置するための方法 |
WO2014084027A1 (ja) * | 2012-11-28 | 2014-06-05 | 独立行政法人放射線医学総合研究所 | 細胞膜透過性の線維芽細胞増殖因子の医療用途 |
Non-Patent Citations (2)
Title |
---|
HUANG JUEN, ET AL., JOURNAL OF GUANGXI MEDICAL UNIVERSITY, vol. 19, no. 1, JPN6019042408, 2002, pages 24 - 6, ISSN: 0004145252 * |
PAN, R.L. ET AL.: "Low-Molecular-Weight Fibroblast Growth Factor 2 Attenuates Hepatic Fibrosis by Epigenetic Down-Regul", HEPATOLOGY, vol. 61, no. 5, JPN6019002917, 23 March 2015 (2015-03-23), pages 1708 - 20, ISSN: 0003968539 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109265553A (zh) * | 2018-08-23 | 2019-01-25 | 许瑞安 | 一种细胞珠蛋白与方格星虫纤溶酶的融合蛋白 |
CN109265553B (zh) * | 2018-08-23 | 2022-04-12 | 许瑞安 | 一种细胞珠蛋白与方格星虫纤溶酶的融合蛋白 |
Also Published As
Publication number | Publication date |
---|---|
JP6675150B2 (ja) | 2020-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Koeppen et al. | Interplay of hypoxia and A2B adenosine receptors in tissue protection | |
KR101438362B1 (ko) | 췌장암을 치료하는 방법 | |
JP7079937B2 (ja) | 肺血管疾患を治療するための組成物および方法 | |
JP2014527402A (ja) | 代謝障害及び疾患の治療のための組成物、使用及び方法 | |
WO2011145723A1 (ja) | メタボリックシンドロームの予防又は治療方法 | |
Su et al. | The local HIF-2α/EPO pathway in the bone marrow is associated with excessive erythrocytosis and the increase in bone marrow microvessel density in chronic mountain sickness | |
EP3476863A1 (en) | Anti-cd5l antibody and uses thereof | |
KR20230109668A (ko) | 간-특이적 Wnt 신호 증강 분자 및 그의 용도 | |
JP2023139101A (ja) | 幹細胞遊走剤を使用した糖尿病治療 | |
Akashi et al. | Knockout of endothelin type B receptor signaling attenuates bleomycin-induced skin sclerosis in mice | |
US11719696B2 (en) | Methods and compounds for diagnosing threonyl-tRNA synthetase-associated diseases and conditions | |
Yu et al. | (Pro) renin receptor RNA interference silencing attenuates diabetic cardiomyopathy pathological process in rats | |
US20130004506A1 (en) | Method for treating pathologies associated with hypoxia using mif inhibitors | |
CN113372435A (zh) | 一种促进血管新生的多肽及其制药用途 | |
Yang et al. | HMGB1 in macrophage nucleus protects against pressure overload induced cardiac remodeling via regulation of macrophage differentiation and inflammatory response | |
JP6675150B2 (ja) | サイトグロビン発現増強剤 | |
US11225653B2 (en) | Methods and compounds for reducing threonyl-tRNA synthetase activity | |
US20060034832A1 (en) | Cell death inhibitor | |
JP6854515B2 (ja) | 解糖系代謝制御物質のスクリーニング方法及び解糖系代謝制御剤 | |
CN115429879A (zh) | 靶向抑制gata3在促进肝脏再生及改善肝损伤中的应用 | |
Vu et al. | Deficiency in ST2 signaling ameliorates RSV-associated pulmonary hypertension | |
WO2016065877A1 (zh) | Cd166作为肝癌诊断血清标志物的应用及其试剂盒 | |
Huang et al. | The lymphocyte adapter protein: A negative regulator of myocardial ischemia/reperfusion injury | |
WO2009113495A1 (ja) | 肝癌特異的発現遺伝子による肝癌の検査方法並びに肝癌の治療及び予防剤 | |
Yu et al. | Bone marrow mesenchymal stem cells derived from juvenile macaques reversed the serum protein expression profile in aged macaques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A80 | Written request to apply exceptions to lack of novelty of invention |
Free format text: JAPANESE INTERMEDIATE CODE: A80 Effective date: 20150420 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180323 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20181227 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190205 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190408 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190520 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20190724 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191105 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191224 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20191224 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200212 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200310 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6675150 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |